Soliton, Inc. (SOLY)

IRVINE, Calif., Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY).

The company's absorption into AbbVie will apparently occur very, very soon.

Wall Street Breakfast (Podcast)

NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction.

Soliton (SOLY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Soliton, Inc. (NasdaqGS: SOLY) to AbbVie, Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Soliton will receive only $22.60 in cash for each share of Soliton that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet

HOUSTON, May 12, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today reported financial results for the first quarter ended March 31, 2021. Recent Company Highlights: Received FDA 510(k) clearance for short-term improvement in the appearance of cellulite; Selected RESONIC™ as the brand name for the Company's Rapid Acoustic Pulse (RAP) device; Received FDA Special 510(k) clearance for modifications to the RESONIC device to facilitate ease of use in commercial settings; Successfully completed all required safety testing including Quality System/Current Good Manufacturing Practice regulations for medical devices (21 CFR Part 820) inspection from the FDA; Expanded sales team through appointment of Sean J.

MILWAUKEE, May 10, 2021 /PRNewswire/ -- Ademi LLP is investigating Soliton (NASDAQ: SOLY) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the action: https://www.ademilaw.com/case/soliton-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK, May 10, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Soliton, Inc. ("Soliton" or the "Company") (NASDAQ: SOLY) in connection with the proposed acquisition of the Company by Allergan Aesthetics, an AbbVie company (NYSE: ABBV). Under the terms of the merger agreement, Allergan Aesthetics will pay Soliton shareholders $22.60 in cash for each Soliton share that they own.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Soliton, Inc. (NASDAQ: SOLY) to Allergan Aesthetics for $22.60 per share in cash is fair to Soliton shareholders. Halper Sadeh encourages Soliton shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Soliton an

The stock price of Soliton Inc (NASDAQ: SOLY) increased by over 20% during intraday trading. This is why it happened.

IRVINE, Calif. and HOUSTON, May 10, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONICTM, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite.

HOUSTON, May 5, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced the launch of its highly anticipated Rapid Acoustic Pulse™ (RAP) device — RESONIC™. The dual-platform RESONIC™ device utilizes a first-of-its-kind technology and offers a paradigm-shifting approach to two in-demand procedures: tattoo removal and cellulite treatment.

HOUSTON, May 4, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its first quarter 2021 financial results on Thursday, May 13, 2021, before market open. Soliton will host a conference call on Thursday, May 13, 2021, at 4:30 p.m.

HOUSTON, April 29, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced the U.S. Food and Drug Administration ("FDA") clearance of the Company's special 510(k) for modifications to its RESONIC™ device. "We were thrilled to receive this clearance as it marks the last significant hurdle to our ability to initiate our commercial launch of the improved RESONIC device in the second quarter," stated Brad Hauser, Soliton CEO and President.

HOUSTON, April 27, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the 52-week results from its pivotal cellulite trial have been accepted for an oral presentation at the American Society for Laser Medicine and Surgery Virtual Annual Conference, held May 15-16, 2021. "We are honored to present new long-term cellulite data at the ASLMS annual conference.